Abstract 233P
Background
Protein polybromo-1 (PB1) encoded by the PBRM1 gene is involved in chromatin-remodeling processes as a part of the SWI/SNF complex. Pathogenic variants of PBRM1 gene are commonly encountered in ccRCC. Much attention has been drawn to the predictive potential of PBRM1 to immunotherapeutic agents’ response in solid tumors. This work aims to establish an interconnection between PBRM1 loss and TIME of ccRCC.
Methods
The ccRCC cohort was obtained from the Cancer Genome Atlas Program (TCGA). Patients were stratified based on the presence of PBRM1 pathological variants into wild type group (n = 213) or mutant group (n = 153). TIME was evaluated through the enrichment of immunological processes-related gene sets using gene set enrichment analysis (GSEA) within the hallmarks of cancer and ontology gene sets. A gene set was considered significantly enriched with a P-value < .05 and a false discovery rate (FDR) ≤ 0.25. Immune cells infiltration was explored using precalculated infiltration scores of xCell. T-cell dysfunction score was obtained from TIDE server.
Results
GSEA illustrated enrichments in three immunological sets within the hallmarks of cancer, including TNF-α signaling through NF-κB (enrichment score (ES) = 0.43, Q value < .001, FDR = 0.007), INF-α response (ES = 0.34, Q value = .03, FDR = 0.190), and INF-γ response (ES = 0.39, Q value < .001, FDR = 0.022). Gene ontology sets screening highlighted the effect of PBRM1 loss on CXCR chemokine receptor binding (ES = 0.75, Q value < .001, FDR = 0.202) with no enriched sets within the cellular component or biological process sections. The mutant group showed a significant CD8+ T-cells depletion alongside reduced infiltration of eosinophils, cancer-associated fibroblasts, M1 macrophages, and T helper 2 cells. PBRM1 damage did not induce a T-cell dysfunction (z score = 0.726, P = .468). In addition, PBRM1 loss was correlated with a superior response to nivolumab in a cohort of 35 patients (fold change = 58.7 and P = .0123).
Conclusions
PBRM1 Loss induces global transcription alternations that impact many immunological processes. Such phenomena could be associated with the positive correlation to immunotherapy response in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract